Greenwich Lifesciences Net Income
| GLSI Stock | USD 29.00 3.81 15.13% |
As of the 7th of February, Greenwich Lifesciences retains the Risk Adjusted Performance of 0.2245, downside deviation of 6.81, and Market Risk Adjusted Performance of 0.9411. Greenwich Lifesciences technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Greenwich Lifesciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Greenwich Lifesciences' valuation are provided below:We have found one hundred nine available fundamental trends for Greenwich Lifesciences, which can be analyzed and compared to other ratios and to its competitors. Traders should compare all of Greenwich Lifesciences regular fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. The Greenwich Lifesciences' current Market Cap is estimated to increase to about 276.3 M. The Greenwich Lifesciences' current Enterprise Value is estimated to increase to about 258.7 M This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -14.2 M | -13.5 M | |
| Net Loss | -14.2 M | -13.5 M | |
| Net Loss | -4.1 M | -4.3 M | |
| Net Loss | (1.40) | (1.33) | |
| Net Income Per E B T | 0.90 | 0.80 |
Greenwich | Net Income | Build AI portfolio with Greenwich Stock |
The Net Income trend for Greenwich Lifesciences offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Greenwich Lifesciences is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Greenwich Lifesciences' Net Income Growth Pattern
Below is the plot of the Net Income of Greenwich Lifesciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Greenwich Lifesciences financial statement analysis. It represents the amount of money remaining after all of Greenwich Lifesciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Greenwich Lifesciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Greenwich Lifesciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (15.79 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Greenwich Net Income Regression Statistics
| Arithmetic Mean | (4,961,802) | |
| Coefficient Of Variation | (102.51) | |
| Mean Deviation | 4,165,435 | |
| Median | (1,689,655) | |
| Standard Deviation | 5,086,516 | |
| Sample Variance | 25.9T | |
| Range | 14.2M | |
| R-Value | (0.83) | |
| Mean Square Error | 8.5T | |
| R-Squared | 0.69 | |
| Significance | 0.000034 | |
| Slope | (838,662) | |
| Total Sum of Squares | 414T |
Greenwich Net Income History
Other Fundumenentals of Greenwich Lifesciences
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Greenwich Lifesciences Net Income component correlations
Greenwich Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Greenwich Lifesciences is extremely important. It helps to project a fair market value of Greenwich Stock properly, considering its historical fundamentals such as Net Income. Since Greenwich Lifesciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Greenwich Lifesciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Greenwich Lifesciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Greenwich introduce new products? Factors like these will boost the valuation of Greenwich Lifesciences. Market participants price Greenwich higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Greenwich Lifesciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Greenwich Lifesciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Greenwich Lifesciences' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Greenwich Lifesciences' market price signifies the transaction level at which participants voluntarily complete trades.
Greenwich Lifesciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Greenwich Lifesciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Greenwich Lifesciences.
| 11/09/2025 |
| 02/07/2026 |
If you would invest 0.00 in Greenwich Lifesciences on November 9, 2025 and sell it all today you would earn a total of 0.00 from holding Greenwich Lifesciences or generate 0.0% return on investment in Greenwich Lifesciences over 90 days. Greenwich Lifesciences is related to or competes with Cognition Therapeutics, Atossa Genetics, Tevogen Bio, Oncolytics Biotech, Surrozen, TuHURA Biosciences, and Seer. Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer imm... More
Greenwich Lifesciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Greenwich Lifesciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Greenwich Lifesciences upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 6.81 | |||
| Information Ratio | 0.2566 | |||
| Maximum Drawdown | 36.51 | |||
| Value At Risk | (11.54) | |||
| Potential Upside | 19.77 |
Greenwich Lifesciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Greenwich Lifesciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Greenwich Lifesciences' standard deviation. In reality, there are many statistical measures that can use Greenwich Lifesciences historical prices to predict the future Greenwich Lifesciences' volatility.| Risk Adjusted Performance | 0.2245 | |||
| Jensen Alpha | 2.02 | |||
| Total Risk Alpha | 1.39 | |||
| Sortino Ratio | 0.3123 | |||
| Treynor Ratio | 0.9311 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Greenwich Lifesciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Greenwich Lifesciences February 7, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.2245 | |||
| Market Risk Adjusted Performance | 0.9411 | |||
| Mean Deviation | 6.41 | |||
| Semi Deviation | 5.78 | |||
| Downside Deviation | 6.81 | |||
| Coefficient Of Variation | 374.01 | |||
| Standard Deviation | 8.29 | |||
| Variance | 68.75 | |||
| Information Ratio | 0.2566 | |||
| Jensen Alpha | 2.02 | |||
| Total Risk Alpha | 1.39 | |||
| Sortino Ratio | 0.3123 | |||
| Treynor Ratio | 0.9311 | |||
| Maximum Drawdown | 36.51 | |||
| Value At Risk | (11.54) | |||
| Potential Upside | 19.77 | |||
| Downside Variance | 46.39 | |||
| Semi Variance | 33.38 | |||
| Expected Short fall | (7.52) | |||
| Skewness | 0.3716 | |||
| Kurtosis | 0.1401 |
Greenwich Lifesciences Backtested Returns
Greenwich Lifesciences is not too volatile given 3 months investment horizon. Greenwich Lifesciences holds Efficiency (Sharpe) Ratio of 0.28, which attests that the entity had a 0.28 % return per unit of risk over the last 3 months. We are able to interpolate and collect twenty-eight different technical indicators, which can help you to evaluate if expected returns of 2.36% are justified by taking the suggested risk. Use Greenwich Lifesciences Market Risk Adjusted Performance of 0.9411, risk adjusted performance of 0.2245, and Downside Deviation of 6.81 to evaluate company specific risk that cannot be diversified away. Greenwich Lifesciences holds a performance score of 21 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 2.37, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Greenwich Lifesciences will likely underperform. Use Greenwich Lifesciences value at risk, and the relationship between the jensen alpha and skewness , to analyze future returns on Greenwich Lifesciences.
Auto-correlation | 0.51 |
Modest predictability
Greenwich Lifesciences has modest predictability. Overlapping area represents the amount of predictability between Greenwich Lifesciences time series from 9th of November 2025 to 24th of December 2025 and 24th of December 2025 to 7th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Greenwich Lifesciences price movement. The serial correlation of 0.51 indicates that about 51.0% of current Greenwich Lifesciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.51 | |
| Spearman Rank Test | 0.48 | |
| Residual Average | 0.0 | |
| Price Variance | 16.11 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Greenwich Lifesciences reported net income of (15.79 Million). This is 104.63% lower than that of the Biotechnology sector and 122.54% lower than that of the Health Care industry. The net income for all United States stocks is 102.77% higher than that of the company.
Greenwich Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Greenwich Lifesciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Greenwich Lifesciences could also be used in its relative valuation, which is a method of valuing Greenwich Lifesciences by comparing valuation metrics of similar companies.Greenwich Lifesciences is currently under evaluation in net income category among its peers.
Greenwich Lifesciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Greenwich Lifesciences from analyzing Greenwich Lifesciences' financial statements. These drivers represent accounts that assess Greenwich Lifesciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Greenwich Lifesciences' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 314.9M | 196.3M | 135.2M | 146.2M | 168.1M | 276.3M | |
| Enterprise Value | 287.7M | 182.8M | 128.2M | 142.1M | 163.4M | 258.7M |
Greenwich Lifesciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Greenwich Lifesciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Greenwich Lifesciences' managers, analysts, and investors.Environmental | Governance | Social |
Greenwich Lifesciences Institutional Holders
Institutional Holdings refers to the ownership stake in Greenwich Lifesciences that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Greenwich Lifesciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Greenwich Lifesciences' value.| Shares | Hightower Advisors, Llc | 2025-06-30 | 17 K | Goldman Sachs Group Inc | 2025-06-30 | 16.5 K | Bank Of New York Mellon Corp | 2025-06-30 | 14.6 K | Citadel Advisors Llc | 2025-06-30 | 13.8 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 11.8 K | Barclays Plc | 2025-06-30 | 10.6 K | Rhumbline Advisers | 2025-06-30 | 9 K | New York State Common Retirement Fund | 2025-06-30 | 6 K | Bank Of America Corp | 2025-06-30 | 5.2 K | Blackrock Inc | 2025-06-30 | 367.2 K | Vanguard Group Inc | 2025-06-30 | 269 K |
Greenwich Fundamentals
| Return On Equity | -5.43 | ||||
| Return On Asset | -2.54 | ||||
| Current Valuation | 371.37 M | ||||
| Shares Outstanding | 13.85 M | ||||
| Shares Owned By Insiders | 50.71 % | ||||
| Shares Owned By Institutions | 9.52 % | ||||
| Number Of Shares Shorted | 1.55 M | ||||
| Price To Book | 171.71 X | ||||
| EBITDA | (15.79 M) | ||||
| Net Income | (15.79 M) | ||||
| Cash And Equivalents | 15.64 M | ||||
| Cash Per Share | 1.22 X | ||||
| Total Debt | 1.56 M | ||||
| Current Ratio | 65.74 X | ||||
| Book Value Per Share | 0.16 X | ||||
| Cash Flow From Operations | (7.27 M) | ||||
| Short Ratio | 1.82 X | ||||
| Earnings Per Share | (1.46) X | ||||
| Target Price | 47.5 | ||||
| Beta | 1.49 | ||||
| Market Capitalization | 349 M | ||||
| Total Asset | 4.09 M | ||||
| Retained Earnings | (66.15 M) | ||||
| Working Capital | 2.53 M | ||||
| Net Asset | 4.09 M |
About Greenwich Lifesciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Greenwich Lifesciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Greenwich Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Greenwich Lifesciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is there potential for Biotechnology market expansion? Will Greenwich introduce new products? Factors like these will boost the valuation of Greenwich Lifesciences. Market participants price Greenwich higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Greenwich Lifesciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Greenwich Lifesciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Greenwich Lifesciences' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Greenwich Lifesciences' market price signifies the transaction level at which participants voluntarily complete trades.